MDMs have been shown to promote ovarian cancer cell survival by activating the STAT3 signaling pathway, whereas TRMs have been associated with ovarian cancer cell proliferation and invasion of the metastatic niches at the peritoneal cavity and omentum [172, 173, 174, 175]. Here, STAT3 is linked to ovarian carcinoma.